The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Date results information initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
A pilot study to increase the in vivo safety and infectivity of an in vitro expanded Plasmodium falciparum 3D7-MBE008 master cell bank in healthy subjects
Scientific title
A pilot study to increase the in vivo safety and infectivity of an in vitro expanded Plasmodium falciparum 3D7-MBE008 master cell bank in healthy subjects
Secondary ID [1] 298739 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malaria 313668 0
Condition category
Condition code
Infection 312083 312083 0 0
Other infectious diseases

Study type
Description of intervention(s) / exposure
This study will evaluate the in vivo safety and infectivity of a Plasmodium falciparum 3D7-MBE008 master cell bank (MCB) in healthy subjects using the induced blood stage malaria (IBSM) model. The study will be conducted in up to 2 subjects. The safety data review team (SDRT) will review the parasitaemia and safety data obtained from the first subject up until the end of Riamet® treatment before the second subject is inoculated with the malaria challenge agent.
The malaria challenge agent, containing an estimated ~2,800 viable P. falciparum 3D7 parasite-infected RBCs in a volume of 2 mL, will be administered once intravenously on Day 0. The subject will undergo intravenous cannulation with an appropriate gauge cannula. The challenge agent will be injected immediately by an infectious disease physician, and the cannula again flushed with 5-10 mL of clinical grade saline. The cannula will then be removed, and haemostasis ensured by use of an appropriate dressing. The subject will be observed for a minimum of 60 minutes after inoculation.
Subjects will be intravenously inoculated with P. falciparum-infected human erythrocytes on Day 0 (approximately 2,800 viable parasites). Subjects will be monitored daily via phone call or text message on Days 1 to 3 to solicit any adverse events (AEs). Subjects will then come to the clinical unit twice daily from Day 4, separated by approximately 12 hours, for safety assessments and to monitor the progression of parasitaemia by collecting blood samples and performing qPCR targeting the gene encoding P. falciparum 18S rRNA.
Antimalarial treatment with artemether/lumefantrine (Riamet®) will be initiated when parasitaemia reaches =10,000 parasites/mL. Subjects will be admitted to the clinical unit for earlier treatment if:
• they have a malaria clinical score greater than or equal to 6
• or if they experience an SAE,
• or if they have a CTCAE grade 3 AE deemed possibly related to malaria and not self-resolved or relieved with concomitant medications,
• or if the Principal Investigator (PI) or Co-Investigator (Co-I), both of whom are infectious diseases physicians, considers it necessary for subject safety. In this situation, the PI or Co-I will consult with the independent medical monitor; however, antimalarial medication may be administered prior to receiving approval if immediate treatment is deemed necessary for subject safety.
Following initiation of treatment, subjects will be followed up as inpatients for at least 24 hours to ensure tolerance of the first three doses of Riamet® and adequate clinical response. Follow-up will then continue on an out-patient basis at 36, 48 and 72 hours post-treatment initiation for continued Riamet® dosing, safety monitoring, and to ensure clearance of parasitaemia. Additional visits may occur at the PI or Co-I’s discretion based on results of safety and parasitaemia assessments. Follow-up safety assessments will occur on Day 30±2 (phone call only), Day 60±2 (phone call only) and Day 90±2 (EOS).
Primacin® (primaquine) may also be administered as a single oral dose if gametocytes are detected using qRT-PCR. The decision to administer primaquine will be made by the PI or Co-I in consultation with the independent medical monitor.
Intervention code [1] 315056 0
Treatment: Other
Comparator / control treatment
No control group
Control group

Primary outcome [1] 320787 0
Adverse events including their severity, seriousness, and causality. These may include common malaria symptoms such as fever, headache, malaise, myalgia and lethargy. Safety assessments including physical examination, clinical laboratory analysis (biochemistry, haematology, and urinalysis), malaria clinical score recording, and electrocardiographs.
Timepoint [1] 320787 0
Adverse event recording: at all clinic visits from parasite inoculation to Day 90+/-2.
Physical examinations: complete physical examinations at screening and Day 11; abbreviated physical examinations prior to parasite inoculum, on clinic admission prior to Riamet® treatment; symptom directed physical examination will also be performed when signs or symptoms of malaria are identified if clinically indicated.
Vital signs: screening, parasite inoculation, and from Day 4 to Day 11.
Biochemistry and haematology (including iron studies): screening, Day -3 to Day -1 safety visit (if required), on clinic admission prior to Riamet® treatment, prior to exit of confinement, Day 11 and Day 90+/-2 (iron studies only)
Urinalysis: screening, Day -3 to Day -1 safety visit (if required), on clinic admission prior to Riamet® treatment and Day 11.
Secondary outcome [1] 372842 0
The presence of parasites in blood samples after inoculation.

Timepoint [1] 372842 0
qPCR: prior to Riamet® treatment and at approximately 2, 4, 8, 12, 16, 20, 24, 36, 48 and 72 hours after Riamet®treatment.
Secondary outcome [2] 372843 0
The growth rate of parasites in subjects after inoculation until Riamet® treatment.
Timepoint [2] 372843 0
qPCR: following inoculation and prior to Riamet® treatment.
Secondary outcome [3] 372844 0
The parasite reduction ratio (PRR) the corresponding parasite clearance half-life and the corresponding parasite clearance half-life. This is a composite outcome.
Timepoint [3] 372844 0
qPCR: prior to Riamet® treatment and at approximately 2, 4, 8, 12, 16, 20, 24, 36, 48 and 72 hours after Riamet®treatment.

Key inclusion criteria
1. Adult male and female (non-pregnant, non-lactating) subjects between 18 and 55 years of age inclusive, who do not live alone (from inoculation day until the end of the antimalarial treatment) and will be contactable and available for the duration of the trial and up to 2 weeks following the End of Study visit
2. Body weight minimum 50 kg, body mass index between 18 and 32 kg/m2, inclusive.
3. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
4. Normal standard 12-lead ECG after 5 minutes resting in supine position.
5. Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects enrolled in this study.
Minimum age
18 Years
Maximum age
55 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Any history of malaria or participation in a previous malaria challenge study.
2. Must not have travelled to or lived (>2 weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region during the course of the study.
3. Has evidence of increased cardiovascular disease risk.
4. History of splenectomy.
5. Presence of acute infectious disease or fever (e.g., sublingual temperature greater than or equal to 38.5 degrees C) within the 5 days prior to inoculation with malaria parasites.
6. Evidence of acute illness within the 4 weeks prior to screening that the Investigator deems may compromise subject safety.
7. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion, e.g. gastrectomy, diarrhoea.
8. Participation in any investigational product study within the 12 weeks preceding the study.
9. Blood donation of any volume within 1 month before inclusion, or participation in any research study involving blood sampling (more than 450 mL/unit of blood), or blood donation to a blood bank during the 8 weeks prior to the treatment drug dose in the study.
10. Subject who has ever received a blood transfusion.
11. Any vaccination within the last 28 days.
12. Any recent (less than 6 weeks) or current systemic therapy with an antibiotic or drug with potential antimalarial activity (i.e. chloroquine, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline etc.)
13. Cardiac/QT risk
14. Known hypersensitivity to artesunate or any of its excipients, artemether or other artemisinin derivatives, piperaquine, atovaquone/proguanil hydrochloride, primaquine, or 4-aminoquinolines.
15. Unwillingness to abstain from consumption of grapefruit or Seville oranges from inoculation day until end of antimalarial treatment

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis
This is a pilot study, to investigate the safety and infectivity of the P. falciparum 3D7-MBE008 malaria challenge agent. A sample of two subjects is considered sufficient to meet the study objectives.
The safety of the P. falciparum 3D7-MBE008 malaria challenge agent will be assessed by monitoring of AEs and SAEs including severity and causality. Safety assessments will include physical examination, clinical laboratory analysis, vital signs, electrocardiographs, and malaria clinical score recording.

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 14293 0
Q-Pharm Pty - Clive Berghofer Research Centre (CBCRC) - Herston
Recruitment postcode(s) [1] 27288 0
4007 - Herston

Funding & Sponsors
Funding source category [1] 303296 0
Name [1] 303296 0
Medicines for Malaria Venture
Address [1] 303296 0
Route de Pre-Bois 20, 1215 Geneva
Country [1] 303296 0
Primary sponsor type
QIMR Berghofer Medical Research Institute
300 Herston Road, Herston QLD 4006
Secondary sponsor category [1] 303317 0
Name [1] 303317 0
Address [1] 303317 0
Country [1] 303317 0

Ethics approval
Ethics application status
Ethics committee name [1] 303827 0
QIMR Berghofer Human Research Ethics Committee
Ethics committee address [1] 303827 0
300 Herston Road, Herston QLD 4006
Ethics committee country [1] 303827 0
Date submitted for ethics approval [1] 303827 0
Approval date [1] 303827 0
Ethics approval number [1] 303827 0

Brief summary
The induced blood stage malaria (IBSM) model provides an attractive tool to test the efficacy of vaccines and drugs for non-immune subjects in a rapid and cost effective manner. The purpose of this pilot clinical trial is to characterise the P. falciparum 3D7-MBE008 MCB as a malaria challenge agent for use in future IBSM studies.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 94950 0
A/Prof Bridget Barber
Address 94950 0
QIMR Berghofer Medical Research Institute
300 Herston Rd, Herston QLD 4006
Country 94950 0
Phone 94950 0
+61 7 3362 0498
Fax 94950 0
Email 94950 0
Contact person for public queries
Name 94951 0
Prof James McCarthy
Address 94951 0
QIMR Berghofer Medical Research Institute
300 Herston Rd, Herston QLD 4006
Country 94951 0
Phone 94951 0
+61 7 3845 3636
Fax 94951 0
Email 94951 0
Contact person for scientific queries
Name 94952 0
Prof James McCarthy
Address 94952 0
QIMR Berghofer Medical Research Institute
300 Herston Rd, Herston QLD 4006
Country 94952 0
Phone 94952 0
+61 7 3845 3636
Fax 94952 0
Email 94952 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
All information obtained during the study, including clinic and hospital records, personal information and research data, will be kept confidential.
What supporting documents are/will be available?
No other documents available
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary